Journal of Diabetes and Its Complications
Volume 25, Issue 1 , Pages 25-30 , January 2011

Mutation H63D in the HFE gene confers risk for the development of type 2 diabetes mellitus but not for chronic complications

  • Máikel L. Colli

      Affiliations

    • Corresponding Author InformationCorresponding author. Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, 900035 003 Porto Alegre, RS, Brazil. Tel.: +55 51 2101 8127; fax: +55 51 2101 8777.
    • ,
  • Jorge L. Gross
    • ,
  • Luis H. Canani

Received 22 June 2009 ,Revised 1 December 2009 ,Accepted 10 December 2009.

References 

  1. Andrews NC. The iron transporter DMT1. International Journal of Biochemistry & Cell Biology. 1999;31:991–994
  2. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G–>A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359:211–218
  3. Boelter MC, Gross JL, Canani LH, Costa LA, Lisboa HR, Tres GS, et al. Proliferative diabetic retinopathy is associated with microalbuminuria in patients with type 2 diabetes. Brazilian Journal Medical and Biological Research. 2006;39:1033–1039
  4. Campbell S, George DK, Robb SD, Spooner R, McDonagh TA, Dargie HJ, et al. The prevalence of haemochromatosis gene mutations in the West of Scotland and their relation to ischaemic heart disease. Heart. 2003;89:1023–1026
  5. Canani LH, Capp C, Ng DP, Choo SG, Maia AL, Nabinger GB, et al. The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes. Diabetes. 2005;54:3326–3330
  6. Cardoso CS, Alves H, Mascarenhas M, Goncalves R, Oliveira P, Rodrigues P, et al. Co-selection of the H63D mutation and the HLA-A29 allele: a new paradigm of linkage disequilibrium?. Immunogenetics. 2002;53:1002–1008
  7. Conte D, Manachino D, Colli A, Guala A, Aimo G, Andreoletti M, et al. Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Annals of Internal Medicine. 1998;128:370–373
  8. Cooksey RC, Jouihan HA, Ajioka RS, Hazel MW, Jones DL, Kushner JP, et al. Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis. Endocrinology. 2004;145:5305–5312
  9. Costa LA, Canani LH, Lisboa HR, Tres GS, Gross JL. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabetic Medicine. 2004;21:252–255
  10. Crispim D, Canani LH, Gross JL, Carlessi RM, Tschiedel B, Souto KE, et al. The G1888A variant in the mitochondrial 16S rRNA gene may be associated with type 2 diabetes in Caucasian-Brazilian patients from southern Brazil. Diabetic Medicine. 2005;22:1683–1689
  11. Davis TM, Beilby J, Davis WA, Olynyk JK, Jeffrey GP, Rossi E, et al. Prevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2008;31:1795–1801
  12. Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B. Factors determining glucose tolerance in patients with thalassemia major. Journal of Clinical Endocrinology and Metabolism. 1993;77:478–483
  13. Dubois-Laforgue D, Caillat-Zucman S, Boitard C, Timsit J. Clinical characteristics of type 2 diabetes in patients with mutations of HFE. Diabetes & Metabolism. 2000;26:65–68
  14. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, Larsen LE, Appleyard M, Frandsen M, et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet. 2001;358:1405–1409
  15. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics. 1996;13:399–408
  16. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care. 1999;22:1978–1983
  17. Halsall DJ, McFarlane I, Luan J, Cox TM, Wareham NJ. Typical type 2 diabetes mellitus and HFE gene mutations: a population-based case-control study. Human Molecular Genetics. 2003;12:1361–1365
  18. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. American Journal of Epidemiology. 2001;154:193–206
  19. Hramiak IM, Finegood DT, Adams PC. Factors affecting glucose tolerance in hereditary hemochromatosis. Clinical & Investigative Medicine. 1997;20:110–118
  20. Jeffrey GP, Chakrabarti S, Hegele RA, Adams PC. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nature Genetics. 1999;22:325–326
  21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of Internal Medicine. 1999;130:461–470
  22. Loebstein R, Lehotay DC, Luo X, Bartfay W, Tyler B, Sher GD. Diabetic nephropathy in hypertransfused patients with beta-thalassemia. The role of oxidative stress. Diabetes Care. 1998;21:1306–1309
  23. McClain DA, Abraham D, Rogers J, Brady R, Gault P, Ajioka R, et al. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia. 2006;49:1661–1669
  24. Moczulski DK, Grzeszczak W, Gawlik B. Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care. 2001;24:1187–1191
  25. Peterlin B, Globocnik Petrovic M, Makuc J, Hawlina M, Petrovic D. A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes. Journal of Human Genetics. 2003;48:646–649
  26. Pietrangelo A. Hereditary hemochromatosis. Annual Review of Nutrition. 2006;26:251–270
  27. Qi L, Meigs J, Manson JE, Ma J, Hunter D, Rifai N, et al. HFE Genetic variability, body iron stores, and the risk of type 2 diabetes in U.S. Women. Diabetes. 2005;54:3567–3572
  28. Rochette J, Pointon JJ, Fisher CA, Perera G, Arambepola M, Arichchi DS, et al. Multicentric origin of hemochromatosis gene (HFE) mutations. American Journal of Human Genetics. 1999;64:1056–1062
  29. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. American Journal of Public Health. 1998;88:15–19
  30. Tuomainen TP, Kontula K, Nyyssonen K, Lakka TA, Helio T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in eastern Finland. Circulation. 1999;100:1274–1279
  31. van der AD, Peeters PH, Grobbee DE, Roest M, Marx JJ, Voorbij HM, et al. HFE mutations and risk of coronary heart disease in middle-aged women. European Journal of Clinical Investigation. 2006;36:682–690
  32. Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo MJ. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care. 1997;20:516–519

☆ Conflict of interest: the authors do not have any conflict of interest.

☆☆ This study was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundo de Incentivo à Pesquisa (FIPE) do Hospital de Clínicas de Porto Alegre. LHC was a recipient of a grant from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). MLC is a recipient of a scholarship from the Brazilian Coordination for the Improvement of Higher Education Personnel.

PII: S1056-8727(09)00133-0

doi: 10.1016/j.jdiacomp.2009.12.002

Journal of Diabetes and Its Complications
Volume 25, Issue 1 , Pages 25-30 , January 2011

Article Tools